Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ALBERT L TYDINGS

Allopathic & Osteopathic Physicians Obstetrics & Gynecology Gynecology

NPI
1952364705
CMS profile
361673
Location
COVINGTON, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$375.64

24 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $368.35 23
Education $7.29 1

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ALBERT L TYDINGS

NPI 1952364705 · CMS profile ID 361673

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology / Gynecology

COVINGTON, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1952364705?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ALBERT L TYDINGS, NPI 1952364705, CMS profile ID 361673. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1952364705?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). ALBERT L TYDINGS, NPI 1952364705, CMS profile ID 361673. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1952364705?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
ALBERT L TYDINGS, NPI 1952364705, CMS profile ID 361673, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–24 of 24 matching records. This page contains 24 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1952364705?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

24 matching records · $375.64 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 24 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–24 of 24.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $18.6712/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722163949 CMS
Hologic, LLC $17.4112/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 713513875 CMS
MILLICENT US INC $19.1811/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 721508233 CMS
Merck Sharp & Dohme Corporation $14.4411/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747843045 CMS
AbbVie Inc. $7.2911/05/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722163945 CMS
AbbVie Inc. $19.6711/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722163947 CMS
Mission Pharmacal Company $15.3010/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 712453323 CMS
TherapeuticsMD, Inc. $14.0510/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 745720407 CMS
Avion Pharmaceuticals $14.5710/08/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 742005839 CMS
AbbVie Inc. $17.6110/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722163943 CMS
AbbVie Inc. $17.2209/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722163941 CMS
TherapeuticsMD, Inc. $13.5609/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 745720405 CMS
AbbVie Inc. $16.3008/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722163939 CMS
Merck Sharp & Dohme Corporation $14.9608/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747837543 CMS
AbbVie Inc. $19.0608/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722163937 CMS
TherapeuticsMD, Inc. $15.3507/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 745720401 CMS
Lupin Inc. $16.2407/27/2020 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 719546625 CMS
AbbVie Inc. $17.4107/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722163935 CMS
Bayer HealthCare Pharmaceuticals Inc. $14.7607/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 713633755 CMS
AbbVie Inc. $21.2706/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722163933 CMS
Bayer HealthCare Pharmaceuticals Inc. $13.1206/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 713633085 CMS
TherapeuticsMD, Inc. $13.0506/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 745720397 CMS
AbbVie Inc. $2.3403/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722163931 CMS
AbbVie Inc. $22.8102/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722163929 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $256.51 16
PY2020 $375.64 24
PY2021 $730.38 40
PY2022 $1,123.53 57
PY2023 $769.95 43
PY2024 $478.12 28
PY2025 $912.09 52

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $174,703.18 54
PY2024 Principal investigator $223,687.95 32
PY2023 Principal investigator $466,935.12 58
PY2022 Principal investigator $46,247.57 25
PY2021 Principal investigator $39,641.29 31
PY2020 Principal investigator $103,836.90 24
PY2019 Principal investigator $79,649.33 21

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

54 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $481.50 12/04/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202527490
Principal investigator 1 Sumitomo Pharma America, Inc. $618.80 11/13/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176655449
Principal investigator 1 Sumitomo Pharma America, Inc. $376.60 11/05/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176655140
Principal investigator 1 ABBVIE INC. $6,996.25 11/04/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202520325
Principal investigator 1 ABBVIE INC. $1,526.75 10/09/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202514537
Principal investigator 1 ABBVIE INC. $261.75 09/03/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202508176
Principal investigator 1 Sumitomo Pharma America, Inc. $3,421.44 09/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176646938
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 08/15/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A PHASE 1/2, RANDOMIZED, OBSERVER-BLINDED, MULTI-COUNTRY STUDY TO EVAL No dispute reported 06/30/2026 1192167560
Principal investigator 1 GlaxoSmithKline, LLC. $1,823.00 08/15/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A PHASE 1/2, RANDOMIZED, OBSERVER-BLINDED, MULTI-COUNTRY STUDY TO EVAL No dispute reported 06/30/2026 1192168910
Principal investigator 1 ABBVIE INC. $261.75 08/05/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202502012
Principal investigator 1 Sumitomo Pharma America, Inc. $285.98 08/04/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176643459
Principal investigator 1 Sumitomo Pharma America, Inc. $1,564.60 08/01/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176641902
Principal investigator 1 Sumitomo Pharma America, Inc. $500.00 07/25/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176641334
Principal investigator 1 Sumitomo Pharma America, Inc. $2,590.00 07/25/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176641337
Principal investigator 1 Sumitomo Pharma America, Inc. $390.00 07/25/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176641340
Principal investigator 1 Sumitomo Pharma America, Inc. $1,896.70 07/18/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176640718
Principal investigator 1 Sumitomo Pharma America, Inc. $8,560.00 07/18/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176640722
Principal investigator 1 Sumitomo Pharma America, Inc. $1,731.60 07/18/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176640726
Principal investigator 1 Sumitomo Pharma America, Inc. $618.80 07/18/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176640730
Principal investigator 1 ABBVIE INC. $557.75 07/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202495407
Principal investigator 1 Sumitomo Pharma America, Inc. $6,532.81 07/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176640188
Principal investigator 1 Sumitomo Pharma America, Inc. $1,710.72 07/01/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176636881
Principal investigator 1 Mylan Inc. $27,525.55 06/18/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY No dispute reported 06/30/2026 1238883613
Principal investigator 1 Mylan Inc. $9,500.00 06/16/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY No dispute reported 06/30/2026 1238883611
Principal investigator 1 Mylan Inc. $2,000.00 05/29/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY No dispute reported 06/30/2026 1238883619
Principal investigator 1 Sumitomo Pharma America, Inc. $2,386.80 05/28/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176635079
Principal investigator 1 Sumitomo Pharma America, Inc. $1,193.40 05/28/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176635083
Principal investigator 1 Mylan Inc. $6,348.00 05/15/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY No dispute reported 06/30/2026 1238883615
Principal investigator 1 GlaxoSmithKline, LLC. $5,177.08 05/12/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A PHASE 1/2, RANDOMIZED, OBSERVER-BLINDED, MULTI-COUNTRY STUDY TO EVAL No dispute reported 06/30/2026 1192167556
Principal investigator 1 Mylan Inc. $500.00 05/08/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY No dispute reported 06/30/2026 1238883617
Principal investigator 1 ABBVIE INC. $1,788.50 05/06/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202481693
Principal investigator 1 Sumitomo Pharma America, Inc. $6,770.40 04/17/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176633480
Principal investigator 1 Sumitomo Pharma America, Inc. $1,193.40 04/10/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176633200
Principal investigator 1 ABBVIE INC. $261.75 04/03/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202473619
Principal investigator 1 GlaxoSmithKline, LLC. $2,527.20 03/19/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A PHASE 1/2, RANDOMIZED, OBSERVER-BLINDED, MULTI-COUNTRY STUDY TO EVAL No dispute reported 06/30/2026 1192168914
Principal investigator 1 Sumitomo Pharma America, Inc. $1,620.96 02/19/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176628060
Principal investigator 1 Sumitomo Pharma America, Inc. $1,620.96 02/19/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176628065
Principal investigator 1 Sumitomo Pharma America, Inc. $3,508.56 02/19/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176628068
Principal investigator 1 Sumitomo Pharma America, Inc. $1,891.56 02/19/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176628072
Principal investigator 1 Sumitomo Pharma America, Inc. $1,891.56 02/19/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176628077
Principal investigator 1 Sumitomo Pharma America, Inc. $3,548.16 02/19/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176628081
Principal investigator 1 Sumitomo Pharma America, Inc. $1,973.40 02/19/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176628084
Principal investigator 1 Sumitomo Pharma America, Inc. $3,580.20 02/06/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176626066
Principal investigator 1 ABBVIE INC. $1,321.25 02/05/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
M18-969 - Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202444795
Principal investigator 1 Sumitomo Pharma America, Inc. $1,554.96 01/29/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176624819
Principal investigator 1 Sumitomo Pharma America, Inc. $1,957.56 01/29/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176624823
Principal investigator 1 Sumitomo Pharma America, Inc. $2,921.16 01/29/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176624828
Principal investigator 1 Sumitomo Pharma America, Inc. $1,620.93 01/29/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176624832
Principal investigator 1 Sumitomo Pharma America, Inc. $1,620.93 01/29/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176624836
Principal investigator 1 Sumitomo Pharma America, Inc. $1,891.56 01/29/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176624840
Principal investigator 1 Sumitomo Pharma America, Inc. $3,211.56 01/29/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176624844
Principal investigator 1 Sumitomo Pharma America, Inc. $10,258.56 01/16/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy No dispute reported 06/30/2026 1176624182
Principal investigator 1 Sumitomo Pharma America, Inc. $17,164.22 01/08/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
A PHASE 3B STUDY TO EVALUATE BONE MINERAL DENSITY WITH LONG-TERM USE OF RELUGOLIX COMBINATION TABLET IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS No dispute reported 06/30/2026 1176623931
Principal investigator 1 ABBVIE INC. $166.25 01/02/2025 Non-covered Recipient Entity
CLINICAL TRIALS MANAGEMENT LLC
M18-969 - Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202434527